vs
Cardlytics, Inc.（CDLX）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
Cardlytics, Inc.的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.4倍（$50.9M vs $35.5M），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs -25.5%），Cardlytics, Inc.自由现金流更多（$13.0M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs -9.6%）
Cardlytics是一家领先的购买智能与广告技术企业，与多家大型银行合作分析匿名消费者交易数据，为消费品牌、零售商及服务商提供基于真实消费行为的精准效果广告投放服务，核心业务覆盖北美与英国地区。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
CDLX vs RXRX — 直观对比
营收规模更大
CDLX
是对方的1.4倍
$35.5M
营收增速更快
RXRX
高出707.2%
-25.5%
自由现金流更多
CDLX
多$60.3M
$-47.3M
两年增速更快
RXRX
近两年复合增速
-9.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $50.9M | $35.5M |
| 净利润 | — | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | -12.0% | -304.8% |
| 净利率 | — | -304.2% |
| 营收同比 | -25.5% | 681.7% |
| 净利润同比 | — | 39.6% |
| 每股收益（稀释后） | $-0.15 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDLXRXRX
| Q4 25 | $50.9M | $35.5M | ||
| Q3 25 | $47.0M | $5.2M | ||
| Q2 25 | $58.0M | $19.2M | ||
| Q1 25 | $56.4M | $14.7M | ||
| Q4 24 | $68.3M | $4.5M | ||
| Q3 24 | $61.1M | $26.1M | ||
| Q2 24 | $64.0M | $14.4M | ||
| Q1 24 | $62.2M | $13.8M |
净利润CDLXRXRX
| Q4 25 | — | $-108.1M | ||
| Q3 25 | $-72.7M | $-162.3M | ||
| Q2 25 | $-9.3M | $-171.9M | ||
| Q1 25 | $-13.3M | $-202.5M | ||
| Q4 24 | — | $-178.9M | ||
| Q3 24 | $-145.2M | $-95.8M | ||
| Q2 24 | $-4.3M | $-97.5M | ||
| Q1 24 | $-24.3M | $-91.4M |
毛利率CDLXRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率CDLXRXRX
| Q4 25 | -12.0% | -304.8% | ||
| Q3 25 | -146.6% | -3327.6% | ||
| Q2 25 | -22.0% | -916.8% | ||
| Q1 25 | -24.9% | -1297.9% | ||
| Q4 24 | -12.2% | -4042.4% | ||
| Q3 24 | -243.1% | -377.1% | ||
| Q2 24 | -24.7% | -697.4% | ||
| Q1 24 | -36.7% | -698.4% |
净利率CDLXRXRX
| Q4 25 | — | -304.2% | ||
| Q3 25 | -154.7% | -3135.3% | ||
| Q2 25 | -16.0% | -894.2% | ||
| Q1 25 | -23.5% | -1373.3% | ||
| Q4 24 | — | -3935.5% | ||
| Q3 24 | -237.6% | -367.5% | ||
| Q2 24 | -6.7% | -676.6% | ||
| Q1 24 | -39.0% | -662.4% |
每股收益（稀释后）CDLXRXRX
| Q4 25 | $-0.15 | $-0.17 | ||
| Q3 25 | $-1.36 | $-0.36 | ||
| Q2 25 | $-0.18 | $-0.41 | ||
| Q1 25 | $-0.26 | $-0.50 | ||
| Q4 24 | $-0.36 | $-0.56 | ||
| Q3 24 | $-2.90 | $-0.34 | ||
| Q2 24 | $-0.09 | $-0.40 | ||
| Q1 24 | $-0.56 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $48.7M | $743.3M |
| 总债务越低越好 | $212.6M | $9.6M |
| 股东权益账面价值 | $-6.5M | $1.1B |
| 总资产 | $285.6M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资CDLXRXRX
| Q4 25 | $48.7M | $743.3M | ||
| Q3 25 | $44.0M | $659.8M | ||
| Q2 25 | $46.7M | $525.1M | ||
| Q1 25 | $52.0M | $500.5M | ||
| Q4 24 | $65.6M | $594.4M | ||
| Q3 24 | $67.0M | $427.6M | ||
| Q2 24 | $71.2M | $474.3M | ||
| Q1 24 | $97.8M | $296.3M |
总债务CDLXRXRX
| Q4 25 | $212.6M | $9.6M | ||
| Q3 25 | $214.6M | $11.9M | ||
| Q2 25 | $214.3M | $14.2M | ||
| Q1 25 | $213.9M | $16.4M | ||
| Q4 24 | $213.6M | $19.0M | ||
| Q3 24 | $213.2M | $20.5M | ||
| Q2 24 | $212.9M | $22.9M | ||
| Q1 24 | $257.9M | — |
股东权益CDLXRXRX
| Q4 25 | $-6.5M | $1.1B | ||
| Q3 25 | $-4.7M | $1.0B | ||
| Q2 25 | $58.7M | $919.1M | ||
| Q1 25 | $64.1M | $933.9M | ||
| Q4 24 | $70.0M | $1.0B | ||
| Q3 24 | $69.7M | $524.6M | ||
| Q2 24 | $210.0M | $584.4M | ||
| Q1 24 | $199.1M | $401.2M |
总资产CDLXRXRX
| Q4 25 | $285.6M | $1.5B | ||
| Q3 25 | $292.8M | $1.4B | ||
| Q2 25 | $361.1M | $1.3B | ||
| Q1 25 | $369.1M | $1.3B | ||
| Q4 24 | $392.7M | $1.4B | ||
| Q3 24 | $399.4M | $726.5M | ||
| Q2 24 | $534.4M | $775.9M | ||
| Q1 24 | $569.0M | $557.8M |
负债/权益比CDLXRXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | 3.65× | 0.02× | ||
| Q1 25 | 3.34× | 0.02× | ||
| Q4 24 | 3.05× | 0.02× | ||
| Q3 24 | 3.06× | 0.04× | ||
| Q2 24 | 1.01× | 0.04× | ||
| Q1 24 | 1.29× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $13.0M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $13.0M | $-47.3M |
| 自由现金流率自由现金流/营收 | 25.5% | -133.1% |
| 资本支出强度资本支出/营收 | 0.0% | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $8.8M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流CDLXRXRX
| Q4 25 | $13.0M | $-46.1M | ||
| Q3 25 | $1.8M | $-117.4M | ||
| Q2 25 | $1.2M | $-76.4M | ||
| Q1 25 | $-6.7M | $-132.0M | ||
| Q4 24 | $3.0M | $-115.4M | ||
| Q3 24 | $1.4M | $-59.2M | ||
| Q2 24 | $4.4M | $-82.2M | ||
| Q1 24 | $-17.6M | $-102.3M |
自由现金流CDLXRXRX
| Q4 25 | $13.0M | $-47.3M | ||
| Q3 25 | $1.7M | $-117.6M | ||
| Q2 25 | $903.0K | $-79.6M | ||
| Q1 25 | $-6.8M | $-133.8M | ||
| Q4 24 | $2.9M | $-116.7M | ||
| Q3 24 | $878.0K | $-63.8M | ||
| Q2 24 | $4.1M | $-83.4M | ||
| Q1 24 | $-18.3M | $-109.0M |
自由现金流率CDLXRXRX
| Q4 25 | 25.5% | -133.1% | ||
| Q3 25 | 3.7% | -2272.5% | ||
| Q2 25 | 1.6% | -413.9% | ||
| Q1 25 | -12.1% | -907.4% | ||
| Q4 24 | 4.2% | -2567.7% | ||
| Q3 24 | 1.4% | -244.6% | ||
| Q2 24 | 6.5% | -578.5% | ||
| Q1 24 | -29.4% | -789.9% |
资本支出强度CDLXRXRX
| Q4 25 | 0.0% | 3.5% | ||
| Q3 25 | 0.0% | 4.7% | ||
| Q2 25 | 0.6% | 16.4% | ||
| Q1 25 | 0.2% | 12.4% | ||
| Q4 24 | 0.2% | 28.6% | ||
| Q3 24 | 0.8% | 17.5% | ||
| Q2 24 | 0.4% | 8.2% | ||
| Q1 24 | 1.0% | 48.2% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
